Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Targeted treatments for AML: the revolution

Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. There has recently been a “revolution in targeted treatments” for AML, according to Francesco Lo-Coco, MD, of University Tor Vergata, Rome, Italy. In this interview, Dr Lo-Coco discusses the latest developments in targeted treatments, which include anti-CD33 monoclonal antibodies, the Bcl-2 inhibitor venetoclax in combination with low-dose cytarabine (investigated in a Phase Ib/II open-label study; NCT02287233) and IDH2 inhibitors. Dr Lo-Coco also highlights the importance of minimal residual disease (MRD) in future trials.